GSK doubles down on oncology with $10.6bn Nuvalent takeover
GSK will acquire lung cancer biotech Nuvalent for $10.6bn in one of its largest ever deals, bolstering its pipeline with…
GSK will acquire lung cancer biotech Nuvalent for $10.6bn in one of its largest ever deals, bolstering its pipeline with…